Related Experiment Video
Updated: May 20, 2026
07:04
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
CFTR inhibitors for treating diarrheal disease
1Department of Medicine, University of California-San Francisco, CA, USA.
Clinical Pharmacology and Therapeutics
|August 2, 2012
Summary
Secretory diarrhea, a global health issue, is caused by enterotoxins activating Cl- channels. Inhibiting the cystic fibrosis transmembrane conductance regulator (CFTR) protein shows promise for antidiarrheal therapy.
Area of Science:
- Medical research
- Gastroenterology
- Molecular biology
Background:
- Secretory diarrhea poses a significant global health challenge.
- Enterotoxins trigger excessive intestinal fluid secretion by activating luminal Cl- channels on enterocytes.
- The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a key mediator of cAMP-regulated Cl- secretion in diarrheal diseases like cholera.
Purpose of the Study:
- To explore the potential of inhibiting the CFTR protein as a therapeutic strategy for secretory diarrhea.
- To evaluate the efficacy of small-molecule CFTR inhibitors in preclinical models.
Main Methods:
- Conducted small-molecule screens to identify CFTR inhibitors.
- Determined the half-maximal inhibitory concentration (IC50) of identified inhibitors.
- Performed proof-of-concept studies in animal models of secretory diarrhea.
Main Results:
- Identified potent small-molecule CFTR inhibitors with IC50 values as low as 4 nmol/l.
- Demonstrated the efficacy of CFTR inhibition in preclinical animal models.
Conclusions:
- CFTR is a viable therapeutic target for secretory diarrhea.
- Small-molecule CFTR inhibitors represent a promising new class of antidiarrheal agents.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...